A Study to Compare PK, PD and Safety of the AD-214-02 and Rabeprazole

• Status: Completed
• Trial end date: 2021-03-08
• Target enrollment: 0
• Participant gender: All

Summary

A study to compare safety, pharmacokinetics and pharmacodynamics of AD-214-02 to Rabeprazole in healthy volunteers.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Addpharma Inc.
• Treatments: Rabeprazole

Criteria

Inclusion Criteria:

• Age 19~50 years in healthy volunteers

• BMI is more than 18.0 kg/m^2 , no more than 27.0 kg/m^2

• Subjects who have ability to comprehend the objectives, contents of study and property of study drug before participating in trial and have willingness to sign of informed consent in writing

Exclusion Criteria:

• Presence of medical history or a concurrent disease that may interfere with treatment and safety assessment or completion of this clinical study, including clinically significant disorders in digestive system, neuropsychiatric system, endocrine system, liver, cardiovascular system

• Subjects who judged ineligible by the investigator